Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Rhea-AI Summary

Shane J. Schaffer, Chairman and CEO of Cingulate (NASDAQ: CING), appeared on the nationally syndicated Big Biz Show to discuss Cingulate's lead Phase 3 asset, CTx-1301, for the treatment of ADHD. Schaffer highlighted the company's Precision Timed Release™ (PTR™) drug delivery platform, which aims to advance next-generation pharmaceutical products. The discussion included plans for the commercialization of CTx-1301 and potential applications of PTR™ technology in other therapeutic areas. The Big Biz Show, hosted by Bob “Sully” Sullivan, is broadcast globally through partners like iHeart Radio and the American Forces Network.

Positive

• Shane J. Schaffer discussed Cingulate's lead Phase 3 asset, CTx-1301, highlighting its potential for ADHD treatment.
• Plans for the commercialization of CTx-1301 were outlined, indicating progress in bringing the product to market.
• Cingulate's proprietary PTR™ technology was showcased, potentially attracting investor interest.

Negative

• None.

KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast, to discuss Cingulate’s lead Phase 3 asset CTx-1301 for the treatment of ADHD, its plans for commercialization, and other therapeutic areas where the company’s PTR™ technology may be applied.

The Big Biz Show is nationally syndicated and can be seen and heard around the globe across a multitude of broadcast partners including iHeart Radio and the American Forces Network. Dr. Schaffer’s interview with Big Biz host Bob “Sully” Sullivan and his cast may be viewed here.

For more information about the Big Biz Show visit bigbizshow.com.

About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City. For more information
visit cingulate.com.

Investor Relations
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200

FAQ

What did Shane Schaffer discuss on the Big Biz Show?

Shane Schaffer discussed Cingulate's lead Phase 3 asset, CTx-1301, for ADHD treatment, commercialization plans, and the PTR™ technology.

What is Cingulate's lead Phase 3 asset?

Cingulate's lead Phase 3 asset is CTx-1301, which is being developed for the treatment of ADHD.

What technology platform does Cingulate use?

Cingulate uses the Precision Timed Release™ (PTR™) drug delivery platform to develop next-generation pharmaceutical products.

Where can the Big Biz Show be accessed?

The Big Biz Show can be accessed globally through broadcast partners like iHeart Radio and the American Forces Network.